Effects of theophylline and rolipram on leukotriene C4 (LTC4) synthesis and chemotaxis of human eosinophils from normal and atopic subjects

British Journal of Pharmacology

Volumn 118, Issue 7, 1996, Pages 1727-1735

  Tenor, Hermann ^a   Hatzelmann, Armin ^b   Church, Martin K ^c   Schudt, Christian ^b   Shute, Janis K ^c  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b ALTANA PHARMA AG   (Germany)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

C5a; Chemotaxis; Human eosinophils; Leukotriene C4; PDE activity; Platelet activating factor (PAF); Prostaglandin E2; Rolipram; Theophylline

Indexed keywords

ARACHIDONIC ACID; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; COMPLEMENT COMPONENT C5A; CYCLIC AMP DEPENDENT PROTEIN KINASE; INDOMETACIN; LEUKOTRIENE C4; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E2; PROTEIN KINASE INHIBITOR; ROLIPRAM; SALBUTAMOL; THEOPHYLLINE; THROMBOCYTE ACTIVATING FACTOR;

ARTICLE; ATOPY; CELL SEPARATION; CHEMOTAXIS; CONTROLLED STUDY; ENZYME ACTIVATION; EOSINOPHIL; HUMAN; HUMAN CELL; ICOSANOID METABOLISM; PRIORITY JOURNAL; RADIOIMMUNOASSAY;

EID: 0029900395     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15598.x     Document Type: Article

References (51)

1. 4: comparison of cells from asthmatic subjects and healthy donors. Ann. Allergy, 64, 287-291.
2. BANNER, K.H. & PAGE, C. (1995a). Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs. Br. J. Pharmacol., 114, 93-98.
3. BANNER, K.H., ROBERTS, N. & PAGE, C. (1995). Differential effect of phosphodiesterase IV inhibitors on the proliferation of human peripheral blood mononuclear cells from normals and subjects with atopic dermatitis. Br. J. Pharmacol., 116, 3169-3174.
4. BARNES. P.J. (1995). Cyclic nucleotides and phosphodiesterases and airway functions. Eur. Respir. J., 8, 457-462.
5. BARNES, P.J. & PAUWELS, R. (1994). Theophylline in the management of asthma: time for reappraisal. Eur. Respir. J., 7, 579-591.
6. BAUER, A.C. & SCHWABE, U. (1980). An improved assay of cyclic 3′,5′-nucleotide phosphodiesterase with QAE sephadex A-25. Naunyn-Schmiedeberg's Arch. Pharmacol., 311, 193-198.
7. BEAVO, J.A. & REIFSNYDER, D.H. (1990). Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol. Sci., 11, 150-155.
8. BOUSQUET, J., CHANEZ, P., LACOSTE, J.Y., BARNEON, G., GHAVANIAN, N., ENANDER, I., VENGE, P., AHLSTEDT, S., SIMONYLAFONTAINE, J., GODARD, P. & MICHEL, F.-B. (1990). Eosinophilic inflammation in asthma. New Engl. J. Med., 323, 1033-1039.
9. 4 formation and luminol dependent chemiluminescence by human eosinophils. Pharmacol. Res. Commun., 18, 61-69.
10. BUTLER, J.M., CHAN, S.C., STEVENS, S. & HANIFIN, J.M. (1983). Increased leukocyte histamine release with elevated cyclic AMP-phosphodiesterase activity in atopic dermatitis. J. Allergy Clin. Immunol., 71, 490-497.
11. CHAN, S.C. & HANIFIN, J.M. (1993). Differential inhibitor effects on cyclic adenosine monophosphate-phosphodiesterase isoforms in atopic and normal leukocytes. J. Lab. Clin. Med., 121, 44-51.
12. CHAN, S.C., LI, S.-H. & HANIFIN, J.M. (1993a). Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J. Invest. Dermatol., 100, 681-684.
13. CHAN, S.C., REIFSNYDER, D., BEAVO, J.A. & HANIFIN, J.M. (1993b). Immunocytochemical characterization of the distinct monocyte cyclic AMP-phosphodiesterase from patients with atopic dermatitis. J. Allergy Clin, Immunol., 91, 1179-1188.
14. CONTI, M., NEMOZ, G., SETTE, C. & VICINI, E. (1995). Recent progress in understanding the hormonal regulation of phosphodiesterases. Endocrine Rev., 16, 370-389.
15. DENT, G., GIEMBYCZ, M.A., RABE, K.F. & BARNES, P.J. (1991). Inhibition of eosinophil cyclic nucleotide PDE activity and opsonized zymosan-stimulated respiratory burst by 'type IV' - selective PDE inhibitors. Br. J. Pharmacol., 103, 1339-1346.
16. DENT. G., GIEMBYCZ, M.A., EVANS, P.M., RABE, K.F. & BARNES, P.J. (1994a). Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. J. Pharmacol. Exp. Ther., 271, 1167-1174.
17. DENT, G., GIEMBYCZ, M.A., RABE, K.F., WOLF. B., BARNES, P.J. & MAGNUSSEN, H. (1994b). Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition. Am. J. Respir. Cell. Mol. Biol., 10, 565-572.
18. DJUKANOVlC, R., FINNERTY, J.P., LEE, C., WILSON, S., MADDEN, J. & HOLGATE, S. (1995). The effects of theophylline on mucosal inflammation in asthmatic airways: biopsy results. Eur. Respir. J., 8, 831-833.
19. HAKANSSON, L. & VENGE, P. (1994). Priming of eosinophil and neutrophil migratory responses by interleukin 3 and interleukin 5. APMIS, 102, 308-316.
20. HATZELMANN, A., TENOR, H. & SCHUDT, C. (1995). Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions. Br. J. Pharmacol., 114, 821-831.
21. HIDI-NG, R., TENOR, H., SCHUDT, C. & DJUKANOVIC, R. (1995). Inhibition of T-lymphocyte chemotaxis by theophylline. Eur. Respir. J., 8, 206s.
22. KANEKO, T., UEKI, I.F. & NADEL, J.A. (1995). Elevated intracellular cAMP inhibits chemotaxis in human eosinophils. Cellular Signalling, 7, 527-534.
23. KIDNEY, J.C, DOMINGUEZ, M., TAYLOR, P., ROSE, M., CHUNG, K.F. & BARNES, P.J. (1995). Immunomodulation by theophylline in asthma. Am. J. Respir. Crit. Care Med., 151, 1907-1914.
24. 4 production between eosinophils and neutrophils. Int. Arch. Allergy Appl. Immunol., 90, 20-23.
25. 4 formation by purified human eosinophils can be induced by arachidonic acid in the absence of calciumionophore A23187. Agents Actions, 26, 96-98.
26. 4 generation by human leukocytes in vitro. J. Allergy Clin. Immunol. 93, 257.
27. KEUHL, F.A., DOUGHERTY, H.W. & HAM, E.A. (1984). Interactions between prostaglandins and leukotrienes. Biochem. Pharmucol., 33, 1-5.
28. KUEHL, F.A., ZANETTI, M.E., SODERMAN, D.D., MILLER, O.K. & HAM, E.A. (1987). Cyclic AMP-dependent regulation of lipid mediators in white cells. Am. Rev. Respir. Dis., 136, 210-213.
29. LI, S.-H., CHAN, S.C., TOSHITANI, A., LEUNG, D.Y.M. & HANIFIN, J.M. (1992). Synergistic effects of interleukin-4 and interferongamma on monocyte phosphodiesterase activity. J. Invest. Dermatol., 99, 65-70.
30. LOUIS, R., BURY, T., CORHAY, J.L. & RADERMECKER, M. (1992). LY 18655, a phosphodiesterase inhibitor inhibits histamine release from human basophils, lung and skin fragments. Int. J. Immunopharmacol., 14, 191-194.
31. NIELSON, C.P., VESTAL, R.E., STURM, R.J. & HEASLIP, R. (1990). Effects of selective phosphodiesterase inhibitors on the polymorphonuclear leucocyte respiratory burst. J. Allergy Clin. Immunol., 86, 801-808.
32. ORANGE, R.P., KALINER, M.A., LARAIA, P.J. & AUSTEN, K.F. (1971). Immunological release of histamine and slow reacting substance of anaphylaxis from human lung. II. Influence of cellular levels of cyclic AMP. Fed. Proc., 30, 1725-1727.
33. PALFREYMAN, M.N. (1995). Phosphodiesterase type IV inhibitors as antiinflammatory agents. Drugs of the Future, 20, 793-804.
34. RABE, K.F., MUÑOZ, N.M., VITA, A.I., MORTON, B.E., MAGNUSSEN, H. & LEFF, A.R. (1994). Contraction of human bronchial smooth muscle caused by activated human eosinophils. Am. J. Physiol. (Lung Cell. Mol. Physiol.), 267, L325-L334.
35. 4 after bronchial challenge with lysine acetylsalicylate in aspirin-induced asthma. Am. J. Respir. Crit. Care. Med., 151, A37.
36. SCHUDT, C., TENOR, H. & HATZELMANN, A. (1995). PDE isoenzymes as targets for antiasthma drugs. Eur. Respir. J., 8, 1179-1183.
37. SHUTE, J.K., SCHUDT, C. & CHURCH, M.K. (1994). Differential inhibition by phosphodiesterase inhibitors of IL-5 and PAF induced chemotactic responses of normal and atopic human eosinophils. J. Allergy Clin. Immunol., 93, 212.
38. SHUTE, J.K., TENOR, H., CHURCH, M.K. & SCHUDT, C. (1995a). Theophylline inhibits GM-CSF release from eosinophils. Eur. Respir. J., 8, 9s.
39. 2 synthesis. Eur. Respir. J., 8, 99s.
40. SOUNESS, J.E., CARTER, C.M., DIOCEE, B.K., HASSAL, G.A., WOOD, L.J. & TURNER, N.C. (1991). Characterization of guinea pig eosinophil phosphodiesterase activity. Biochem. Pharmacol., 42, 937-945.
41. SPATAFORA, M., CHIAPPARA, G., MERENDINO, A.M., D'AMICO, D., BELLIA, V. & BONSIGNORE, G. (1994). Theophylline suppresses the release of tumor necrosis factor-α by blood monocytes and alveolar macrophages. Eur. Respir. J., 7, 223 228.
42. STEVENSON, D.D. (1987). Proposed mechanisms of aspirin sensitivity reactions. J. Allergy Clin. Immunol., 80, 788-790.
43. SULLIVAN, P.J., BEKIR, S., JAFFAR, Z., PAGE, C.P., JEFFREY, P.K. & COSTELLO, J.F. (1994). Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet, 343, 1006-1008.
44. 4 in response to soluble agonists. J. Immunol., 147, 38555-3861.
45. 4 production by human eosinophils in vitro. J. Immunol., 141, 4291-4297.
46. 4 from eosinophils in asthmatic patients. Allergy, 400, 571-573.
47. TANIMOTO, Y., MARCO, H., BEWTRA, A.K. & TOWNLEY, R.G. (1994). Effects of phosphodiesterase IV inhibitor (WAY-PDE-641) on human eosinophil and neutrophil migration in vitro. J. Allergy Clin. Immunol., 93, 257.
48. TEIXERA, M.M., ROSSI, A.G., WILLIAMS, T.J. & HELLEWELL, P.G. (1994). Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br. J. Pharmacol., 112, 332-340.
49. TENOR, H., HATZELMANN, A., KUPFERSCHMIDT, R., STANCIU, L., DJUKANOVIC, R., SCHUDT, C., WENDEL. A., CHURCH, M.K. & SHUTE, J.K. (1995). Cyclic nucleotide phosphodiesterase isoenzyme activities in human alveolar macrophages. Clin. Exp. Allergy, 25, 625-633.
50. THOMPSON, W.J. & APPLEMAN, M.M. (1979). Assay of cyclic nucleotide phosphodiesterase and resolution of multiple molecular forms of the enzyme. Adv. Cycl. Nucl. Res., 10, 69-92.
51. 4 in leukocytes from allergic asthmatic subjects. Adv. Prost. Thromb. Leukotr. Res., 19, 548-551.